» Articles » PMID: 29382955

Ocular Findings and Ocular Graft-versus-host Disease After Allogeneic Stem Cell Transplantation Without Total Body Irradiation

Overview
Specialty General Surgery
Date 2018 Feb 1
PMID 29382955
Citations 30
Authors
Affiliations
Soon will be listed here.
Abstract

Patients treated with allogeneic stem cell transplantation (allo-SCT) often develop ocular complications. To investigate the ocular findings in young long-term survivors after allo-SCT without TBI, we examined 96 patients more than 5 years after transplantation. All patients were under 30 years of age at transplantation. The mean follow-up time was 16.8 years (range 6.0-26.1 years). The study was a part of the Norwegian Allo Survivorship Study investigating health impairments in young survivors after allo-SCT. Ophthalmological examination included visual acuity, tear break-up time, corneal fluorescein staining, Schirmer I test, tear film osmolarity, biomicroscopy and dilated ophthalmoscopy. In patients with known systemic chronic GVHD (cGVHD), ocular GVHD (oGVHD) diagnosed by clinical examination was compared with diagnosis using National Institutes of Health (NIH) or International Chronic Ocular Graft-vs-Host-Disease (ICCGVHD) Consensus Group criteria. We diagnosed dry eye disease (DED) in 52 patients (54%), cataract in 3 patients (3%) and retinopathy in 1 patient (1%). Systemic cGVHD was a risk factor for DED (OR 4.40, CI 1.33-14.56, p = 0.02). Comparison of diagnostic criteria suggests that the more stringent ICCGVHD criteria can better differentiate DED from oGVHD after allo-SCT as compared with the NIH criteria.

Citing Articles

Application of lacrimal gland ultrasonography in the evaluation of chronic ocular graft-versus-host-disease.

Zhong M, Liu S, Luo J, Zhang Q, Yang Z, Zhang S Front Immunol. 2025; 16:1490390.

PMID: 39975559 PMC: 11836017. DOI: 10.3389/fimmu.2025.1490390.


Epidemiology and risk factors for the development of cicatrizing conjunctivitis in chronic ocular graft-versus-host disease.

Kantor N, Sepulveda-Beltran P, Valdes-Arias D, Locatelli E, Mulpuri L, Gunawardene A Ocul Surf. 2024; 34:341-347.

PMID: 39276859 PMC: 11625611. DOI: 10.1016/j.jtos.2024.09.002.


[Clinical study of the cytokine panel in the diagnosis of ocular chronic graft-versus-host disease].

Cheng X, Ji R, Huan R, Huang S, Fan W, Zhao Y Zhonghua Xue Ye Xue Za Zhi. 2024; 45(3):242-248.

PMID: 38716595 PMC: 11078663. DOI: 10.3760/cma.j.cn121090-20231031-00242.


Ophthalmic Manifestations in Patients with Blood Malignancies.

Rossi C, Buizza A, Alessio G, Borselli M, Taloni A, Carnevali A Hematol Rep. 2024; 16(2):193-203.

PMID: 38651449 PMC: 11036248. DOI: 10.3390/hematolrep16020020.


Development and validation of a diagnostic model for the identification of chronic ocular graft-versus-host disease (oGVHD).

Shen Z, Hu B, Tao L, Ma J, Peng R, Zhao Y Front Med (Lausanne). 2023; 10:1277194.

PMID: 37964878 PMC: 10641834. DOI: 10.3389/fmed.2023.1277194.


References
1.
Coskuncan N, Jabs D, Dunn J, Haller J, Green W, Vogelsang G . The eye in bone marrow transplantation. VI. Retinal complications. Arch Ophthalmol. 1994; 112(3):372-9. DOI: 10.1001/archopht.1994.01090150102031. View

2.
Lemp M . Report of the National Eye Institute/Industry workshop on Clinical Trials in Dry Eyes. CLAO J. 1995; 21(4):221-32. View

3.
Savini G, Prabhawasat P, Kojima T, Grueterich M, Espana E, Goto E . The challenge of dry eye diagnosis. Clin Ophthalmol. 2009; 2(1):31-55. PMC: 2698717. DOI: 10.2147/opth.s1496. View

4.
Lee S, Flowers M . Recognizing and managing chronic graft-versus-host disease. Hematology Am Soc Hematol Educ Program. 2008; :134-41. DOI: 10.1182/asheducation-2008.1.134. View

5.
Nichols K, Mitchell G, Zadnik K . The repeatability of clinical measurements of dry eye. Cornea. 2004; 23(3):272-85. DOI: 10.1097/00003226-200404000-00010. View